Alizyme retained by Merrill Lynch at buy

Alizyme plc was retained by Merrill Lynch at a buy rating with a 170p target, following its receipt of a Special Protocol Assessment from the FDA for a pivotal Phase III study of Renzapride in constipation-predominant irritable bowel syndrome. On the London Stock Exchange, Alizyme shares on Thursday gained 3.06p, or 3.52%, to close at 90.06p on volume of 3.2 million shares versus the three-month running average of 1.1 million.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.